Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

Up to 10 Million Americans Could Lose Medicaid by 2028 Under New Work Requirements

by Team Lumida
April 1, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • Between 5 million and 10 million people could lose Medicaid coverage in 2028 due to work requirements and six-month eligibility redeterminations mandated under the One Big Beautiful Bill signed by President Trump in July
  • 2 to 3.1 million enrollees could lose coverage from the shift to semi-annual eligibility checks alone; an additional 3 to 7 million could be cut due to the new 80-hour monthly work requirement
  • 19% to 37% of those who already work and legally qualify could still be disenrolled due to paperwork and documentation challenges — not because they are ineligible
  • Even in the best-case high-mitigation scenario, Medicaid expansion enrollment drops from 18.4 million to 13.5 million — a loss of nearly 5 million covered lives

What Happened?

A new analysis by the Urban Institute and Robert Wood Johnson Foundation projects that between 5 million and 10 million people could lose Medicaid coverage in 2028 due to sweeping policy changes in the One Big Beautiful Bill, signed into law by President Trump last July. The law requires many adults who enrolled through the ACA Medicaid expansion to document 80 hours per month of work, education, or volunteer activity to maintain coverage. It also mandates eligibility redeterminations every six months instead of annually. Researchers modeled three scenarios — low, medium, and high state-level mitigation — based on how aggressively states work to protect enrollees through automatic data-matching, broader exemption definitions, and accessible documentation processes. Even under the most protective scenario, expansion enrollment falls from 18.4 million to 13.5 million — a decline of nearly 5 million people. Under the low-mitigation scenario, that figure surpasses 8 million.

Why It Matters?

This represents the largest structural change to Medicaid in decades, affecting a program that covers 76 million Americans. The financial exposure for the healthcare sector is significant: hospitals, managed care organizations, and state Medicaid budgets are all heavily dependent on continuous enrollment. The analysis reveals a particularly troubling dynamic — people who already work and qualify for the program could still lose coverage due to documentation burdens. Between 30% and 73% of self-employed enrollees subject to the work mandate could be disenrolled because automatic income verification for the self-employed is technically difficult. Caregivers of family members with disabilities face disenrollment rates of 19% to 52%, even though they are supposed to be exempt. For healthcare investors and operators, this translates directly into higher uncompensated care costs, increased bad debt, and potential pressure on Medicaid managed care plan margins.

What’s Next?

Implementation affects enrollees starting in 2028, giving states roughly two years to build the infrastructure needed to minimize unnecessary coverage losses. States that invest in automatic data-matching and broad exemption definitions will blunt the impact significantly — but political and resource constraints will vary widely. Managed care organizations with large Medicaid books of business should be closely monitoring state-level implementation plans; the difference between high and low mitigation scenarios represents millions of covered lives and billions in premium revenue. Hospital systems should be stress-testing their uncompensated care assumptions now. Congressional debate over further Medicaid cuts — including proposals to cap federal matching funds — is expected to continue through the 2026 budget cycle, adding additional uncertainty to an already volatile policy environment.

Source: Healthcare Dive

Previous Post

Oracle Slashes Thousands of Jobs to Fund Its AI Bet

Next Post

94% of Physicians Have Adopted or Want AI — But Accuracy Concerns Remain the Top Barrier

Recommended For You

GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

by Team Lumida
1 day ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

Shoppers on weight-loss drugs are dropping a clothing size every month, flooding retailers with returns — one online suit seller saw a 50% jump — and forcing the...

Read more

Weight-Loss Drugs Like Ozempic May Also Slow Cancer — Four New Studies Show Striking Results

by Team Lumida
2 weeks ago
Eli Lilly and Novo Nordisk Shares Plunge Amid Ozempic Vision Loss Fears

GLP-1 drugs used for diabetes and obesity are linked to reduced tumor progression, lower cancer mortality, and decreased breast cancer risk across hundreds of thousands of patients in...

Read more

GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

by Team Lumida
3 weeks ago
GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

As 13 million Americans take GLP-1 drugs like Ozempic and Mounjaro, a growing body of research warns the drugs can cause up to 10% lean muscle loss —...

Read more

Hospital at Home Linked to Lower Mortality and Fewer ER Visits, JAMA Study Finds

by Team Lumida
3 weeks ago
dextrose hanging on stainless steel IV stand

A new JAMA Network Open study of Medicare data shows hospital-at-home programs reduce in-hospital mortality, ED visits, and ICU escalations — but adoption is concentrated in urban hospitals...

Read more

8 Evidence-Based Tips for Healthy Eating, According to the NHS

by Team Lumida
4 weeks ago
vegetable salad

From starchy carbs to salt limits, the UK's National Health Service lays out the practical fundamentals of a balanced diet — and most adults are still getting it...

Read more

The FDA Is Fast-Tracking Psychedelics. The Infrastructure to Support Them Isn’t Ready.

by Team Lumida
1 month ago
Abstract colorful psychedelic swirling patterns

Trump's executive order to accelerate psychedelic drug development is welcome — but Bloomberg Opinion's Lisa Jarvis warns the ketamine clinic free-for-all is a cautionary tale the FDA must...

Read more

Ultrasound on a Chip: Butterfly Network’s $4,000 Device Is Taking Medical Imaging Global

by Team Lumida
1 month ago
a person holding a tablet

Butterfly Network's semiconductor-based handheld ultrasound costs a fraction of traditional machines and has reached 150,000 deployments worldwide, pairing AI with imaging to put diagnostics in the hands of...

Read more

Nearly 1 in 8 Americans Now Uses Sleep Aids — and Pharma Is Taking Notice

by Team Lumida
1 month ago
woman sleeping on bed under blankets

A new federal study finds 13% of U.S. adults rely on prescription drugs, OTC supplements, marijuana, or CBD to sleep, as Eli Lilly's $7.8B acquisition of a sleep...

Read more

Amazon One Medical Launches GLP-1 Weight Loss Program at $25 a Month

by Team Lumida
1 month ago
Amazon Targets Rural America: A Game-Changer for Delivery Services

Amazon One Medical is rolling out a weight management program that includes GLP-1 medications, offering compounded pills starting at $25/month with same-day delivery in 3,000 cities.

Read more

Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

by Team Lumida
2 months ago
Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

Melatonin is generally safe for short-term use and non-habit-forming, but it carries real side effects and drug interactions that most users overlook — Mayo Clinic breaks down what...

Read more
Next Post
a man holding a ball in his right hand

94% of Physicians Have Adopted or Want AI — But Accuracy Concerns Remain the Top Barrier

House Rebuke of Canada Tariffs Exposes Political Risk Around Trump’s Trade Agenda

Trump Threatens to Escalate Iran War — But Says End Is 'Very Close'

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Oracle’s Q4 earnings missed expectations but stock jumped ~11% after new cloud deals

Oracle Credit Protection Hits 16-Year High as AI Debt Wave Raises Bubble Fears

December 3, 2025
Silicon Photonics Revolution: Nvidia’s Jankowski Joins Lightmatter

Silicon Photonics Revolution: Nvidia’s Jankowski Joins Lightmatter

July 2, 2024
BYD Shocks Auto Market with 1,300-Mile Hybrids—Can Tesla Keep Up?

BYD Sales Stumble as China’s Electric Car Upstarts Gain Ground

September 2, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018